Preclinical and clinical development of a dengue recombinant subunit vaccine

Vaccine

Volumn 33, Issue 50, 2015, Pages 7126-7134

  Manoff, Susan B ^a   George, Sarah L ^b,c   Bett, Andrew J ^a   Yelmene, Michele L ^d   Dhanasekaran, Govindarajan ^a   Eggemeyer, Linda ^b,c   Sausser, Michele L ^a   Dubey, Sheri A ^a   Casimiro, Danilo R ^a   Clements, David E ^d   Martyak, Timothy ^d   Pai, Vidya ^d   Parks, D Elliot ^d   Coller, Beth Ann G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d HAWAII BIOTECH INC   (United States)

Author keywords

Dengue vaccine; Recombinant; Subunit

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; BILIRUBIN; DENGUE VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS GLYCOPROTEIN; CHOLESTEROL; DRUG COMBINATION; ISCOMATRIX; PHOSPHOLIPID; SAPONIN; VIRUS ANTIBODY;

AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ARTICLE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DROSOPHILA; DRUG TOLERABILITY; FLAVIVIRUS; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERESTHESIA; HYPERGLYCEMIA; IMMUNOGENICITY; INTERFERON PRODUCTION; LEUKOPENIA; MACACA; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIMATE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; ANIMAL; BLOOD; DENGUE; DRUG COMBINATION; GENETICS; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PRECLINICAL STUDY; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHOLESTEROL; CLINICAL TRIALS, PHASE I AS TOPIC; DENGUE; DENGUE VACCINES; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNIZATION SCHEDULE; INTERFERON-GAMMA; MACACA; PHOSPHOLIPIDS; SAPONINS; T-LYMPHOCYTES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84951304447     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.101     Document Type: Article

References (32)

1. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8:S7-S16.
2. Whitehorn J., Farrar J. Dengue. Br Med Bull 2010, 95:161-173.
3. Halstead S. Dengue. Lancet 2007, 370:1644-1652.
4. Tapia-Conyer R., Méndez-Galván J.F., Gallardo-Rincón H. The growing burden of dengue in Latin America. J Clin Virol 2009, 46(Suppl. 2):S3-S6.
5. Anderson K.B., Chunsuttiwat S., Nisalak A., Mammen M.P., Libraty D.H., Rothman A.L., et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007, 369:1452-1459.
6. Suaya J., Shepard D., Ssiqueira J., Martelli C., Lum L., Tan L., et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009, 80:846-855.
7. Clark D.V., Mammen M.P., Nisalak A., Puthimethee V., Endy T.P. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 2005, 72:786-791.
8. Morens D., Fauci A. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 2008, 299:214-216.
9. Guzman A., Istúriz R.E. Update on the global spread of dengue. Int J Antimicrob Agents 2010, 36(Suppl. 1):S40-S42.
10. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
11. Brady O., Gething P., Bhatt S., Messina J., Brownstein J., Hoen A. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012, 6:e1760.
12. Dengue Vaccine Initiative. Available at: [accessed 19.03.15]. http://www.denguevaccines.org/.
13. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239:476-481.
14. Rigau-Pérez J.G., Clark G.G., Gubler D.J., Reiter P., Sanders E.J., Vorndam A.V. Dengue and dengue haemorrhagic fever. Lancet 1998, 352:971-977.
15. Guzman M., Alvarez M., Halstead S. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013, 158:1445-1459.
16. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9:921-927.
17. Halstead S.B. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013, 31:4501-4507.
18. Halstead S.B., Deen J. The future of dengue vaccines. Lancet 2002, 360:1243-1245.
19. Thomas S.J., Endy T.P. Vaccines for the prevention of dengue: development update. Hum Vaccine 2011, 7:674-684.
20. Durbin A.P., Whitehead S.S. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011, 3:1800-1814.
21. Robert Putnak J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23:4442-4452.
22. Clements D., Coller B., Lieberman M., Ogata S., Wang G., Harada K. Development of a recombinant tetravalent dengue virus VACCINE: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28:2705-2715.
23. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29:7267-7275.
24. Modis Y., Ogata S., Clements D., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003, 100:6986-6991.
25. Modis Y., Ogata S., Clements D., Harrison S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004, 427:313-319.
26. Zhang Y., Zhang W., Ogata S., Clements D., Strauss J., Baker T., et al. Conformational changes of the flavivirus E glycoprotein. Structure 2004, 12:1607-1618.
27. Govindarajan D., Meschino S., Guan L., Clements D.E., ter Meulen J., Casimiro D., et al. Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity, and protective efficacy in nonhuman primates. Vaccine 2015, 33:4105-4116.
28. Meschino S, Govindarajan D, Dubey SA, Bennett PS, Senderak E, Coller B, et al. High throughput dengue microneutralization assay for vaccine studies. American Society for Tropical Medicine and Hygiene 2011 Annual Meeting.
29. Tang A., Li F., Freed D.C., Finnefrock A.C., Casimiro D.R., Wang D. A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 2011, 29:8350-8356.
30. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
31. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75:7290-7304.
32. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.